Cingulate Inc

CING30 Nov 2024
Healthcare
$4.13
+0.04 (+3.81%)
Lowest Today
$4.13
Highest Today
$4.44
Today’s Open
$4.13
Prev. Close
$4.2
52 Week High
$152.4
52 Week Low
$1.8
To Invest in Cingulate Inc

Cingulate Inc

Healthcare
CING30 Nov 2024
+0.04 (+3.81%)
1M
3M
6M
1Y
5Y
Low
$4.13
Day’s Range
High
$4.44
4.13
52 Week Low
$1.8
52-Week Range
52 Week High
$152.4
1.8
1 Day
-
1 Week
-9.12%
1 month return
-0.23%
3 month return
-45.47%
6 month return
+502.81%
1 Year return
-28.06%
3 Years return
-95.16%
5 Years return
-
10 Years return
-
Institutional Holdings
Commonwealth Equity Services Inc
0.3
Fidelity Extended Market Index
0.15
Bank of America Corp
0.06
Virtu Financial LLC
0.06
Fidelity Series Total Market Index
0.04
Vanguard Institutional Extnd Mkt Idx Tr
0.02
FMR Inc
0.01

Market Status

Fundamentals
Market Cap
13.49 mln
PB Ratio
1.12
PE Ratio
0
Enterprise Value
3.69 mln
Total Assets
3.49 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Organisation
Cingulate Inc
Employees
13
Industry
Biotechnology
CEO
Dr. Shane J. Schaffer Pharm.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities